Results 91 to 100 of about 5,934 (217)

A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder

Brain Sciences
Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among healthy individuals and patients with post-traumatic stress disorder (PTSD) or major depressive disorder (MDD ...
Mario Renato Velit-Salazar, Paulo R. Shiroma, Eloise Cherian   +2 more
doaj   +1 more source

Psychedelic Therapy and the Role of Music: A Scoping Review of Quantitative Evidence on Subjective and Objective Outcomes

Brain and Behavior, Volume 16, Issue 6, June 2026.
ABSTRACT Purpose Psychedelics have received considerable attention due to their potential in treating psychiatric disorders. The “setting” during psychedelic‐assisted therapy (PAT) is recognized as playing a central role in the experience, during which music features prominently. Although music is theorized as directing and shaping psychedelic sessions,
T. Rowe, T. Hurzeler, E. Towers, E. Louie, K. C. Morley   +4 more
wiley   +1 more source

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects [PDF]

, 2017
Background and Objective: Lysergic acid diethylamide (LSD) is used recreationally and in clinical research. The aim of the present study was to characterize the pharmacokinetics and exposure–response relationship of oral LSD.
Katharina M. Rentsch, Dolder, Patrick C, Liechti, Matthias E, Steuer, Andrea E, Rentsch, Katharina M, Schmid, Yasmin, Andrea E. Steuer, Thomas Kraemer, Dolder, Patrick C., Yasmin Schmid, Matthias E. Liechti, Steuer, Andrea E., Patrick C. Dolder, Rentsch, Katharina M., Liechti, Matthias E., Felix Hammann, Kraemer, Thomas, Hammann, Felix   +17 more
core   +1 more source

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders

Pharmaceuticals
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs).
Tamara Valdez, Valbhi Patel, Nattaphone Senesombath, Zayd Hatahet-Donovan, Mary Hornick   +4 more
doaj   +1 more source

The Prevalence of Substance Use Among Students and Associated Factors: A Systematic Review With Narrative Synthesis

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Substance use is a major public health and social problem that affects individuals of all ages, particularly adolescents and young adults, across every society. School as an educational environment can be suitable for education and orientation towards substances.
Nikta Bazleh
wiley   +1 more source

[[alternative]]Determination of 3,4-Methylenedioxymethamphetamine and Lysergic Acid Diethylamide in Urine by Capillary Electrophoresis/Fluorescence Spectroscopy

, 2010
[[abstract]]3,4-methylenedioxyamphetamine (3,4-MDMA) is a strong central nervous system stimulant. Using nonaqueous capillary electrophoresis/fluorescence detection, the precision of the method was evaluated by measuring the repeatability and ...
Ching Fang, [[author]]方晴, [[author]]Ching Fang, 方晴   +3 more
core  

A Systematic Investigation on the Medicinal Use of Lysergic Acid Diethylamide

, 2021
Gemstone Team ACIDEvidence points to several mechanistic relationships where lysergic acid diethylamide (LSD) alters the serotonergic system in autism spectrum disorders (ASD) and positively impacts ASD-related clinical outcomes.
Foster, Kayla, Pascale, Luke, Nguyen, Thach-Vu, Olson, Caroline, Mohammed, Alan, Hansen, Abigail, Lee, Matthew   +6 more
core   +1 more source

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings

International Journal of Methods in Psychiatric Research, Volume 35, Issue 2, June 2026.
ABSTRACT Objectives For English, the validated part of Psychedelic Experience Scale (PES48) is a four‐factor structure called the Mystical Experience Questionnaire (MEQ30). The other validated part of the PES48 consists of four more factors: two more mystical factors (paradoxicality and connectedness, which together with the MEQ30 form the MEQ40), and ...
Kurt Stocker, Matthias Hartmann, Frederick S. Barrett, William A. Richards, Nathan D. Sepeda, Laura Ley, Anna M. Becker, Friederike Holze, Matthias E. Liechti   +8 more
wiley   +1 more source

Analytically Confirmed Opioid Detections From the Emerging Drugs Network of Australia

Emergency Medicine Australasia, Volume 38, Issue 3, June 2026.
ABSTRACT Objective We describe analytically confirmed opioid‐related presentations to emergency departments (EDs) in Australia. Methods Presentations with analytically confirmed opioid exposure, between January 2021 and December 2024, were identified from the Emerging Drugs Network of Australia (EDNA) Clinical Registry.
J. Soderstrom, C. Weber, S. Greene, K. Isoardi, S. Alfred, V. Tran, P. Stockham, J. Schumann, A. Thompson, D. Fatovich, on behalf of the EDNA Investigators, Jessamine Soderstrom, Jennifer Smith, Daniel Fatovich, Shaun Greene, Sam Alfred, Katherine Isoardi, Andrew Dawson, Anthony Tzannes, Hugh Mitenko, Hwee Min Lee, Kirsty Skinner, Viet Tran, Ben Weber, Vanessa Shaw, Timothy Cook, Courtney Weber, Sharon Waterson, David McCutcheon, Natalie MacCormick, Keith Harris, Francois Oosthuizen, Peter Stockham, Dimitri Gerostamoulos, Andis Graudins, Una Nic Ionmhain, Christopher Reid, Paul Dessauer, Andrew Kozman, Mohan Raghavan, Ellie Kotkis, Craig Gardner, Giles Barrington, Jason White, Samantha Carey, Jennifer Schumann, Eden Smyth, Owen McWilliam, Jolanda Nijmeijer, Elyssia Bourke, Craig Cumming, Thanjira Jiranantakan, Abigail Stafslien‐Dumale, Maurizio Stefani   +53 more
wiley   +1 more source

Lysergic acid diethylamide (LSD) and Psilocybin for the Management of Patients with Persistent Pain: A Potential Role? [PDF]

, 2018
Recently, there has been interest in lysergic acid diethylamide (LSD) and psilocybin for depression, anxiety and fear of death in terminal illness. The aim of this review is to discuss the potential use of LSD and psilocybin for patients with persistent ...
Mark I Johnson, Johnson, MI, Andy Whelan, Whelan, A   +3 more
core   +1 more source